Oculis Holding AG, a global biopharmaceutical company, has appointed Dr. Snehal Shah, an executive leader with over two decades of research & development (R&D) and regulatory experience, to the role of President of R&D.
 
Shah will be responsible for leading research and development strategies, and working towards achieving market authorizations by directing global regulatory activities required for future New Drug Application (NDA) submissions to the U.S. Food and Drug Administration (FDA), and the equivalent for regulators in other territories.

Experience

Shah joins Oculis from Iveric Bio where he served as Chief Regulatory & Product Strategy Officer and led the successful approval of Izervay for Geographic Atrophy in the U.S. He brings over 20 years of global experience in regulatory science, research & development, pharmacovigilance, and product strategy gained at leading large, medium and biotech pharmaceutical companies including Hoffmann La-Roche / Genentech, Noven Pharmaceuticals (Member of the Hisamitsu Group), Kyowa Kirin and Iveric Bio.
 
He has a proven track record of spearheading innovative programs in various therapeutic areas including in ophthalmology for both small molecules and biologics through product development lifecycle phases from conception through commercialization.
 
Riad Sherif, M.D., Chief Executive Officer of Oculis, said, “We are thrilled to welcome Snehal to Oculis as we continue to expand our U.S. footprint. Snehal’s leadership and development expertise, especially in ophthalmology, will be pivotal to advancing our innovative and differentiated pipeline. His extensive strategic experience in leading R&D and regulatory functions, and successful track record of bringing over a dozen market applications to approval will play a pivotal role in our efforts to deliver transformative new therapies to patients suffering from eye diseases.”
 
Shah commented, “I am thrilled to join the exceptionally talented team at Oculis to lead R&D activities during a period of significant momentum and expansion which comes as we advance our leading candidate OCS-01 through Phase 3 trials towards our first anticipated NDA submission and expect the OCS-02 RELIEF Phase 2b trial results this quarter. Oculis’ highly diversified pipeline provides an opportunity to be part of an endeavor that aims to shift the treatment paradigm for ocular disorders, supporting patients throughout their disease continuum, which can lead to vision loss and ultimately blindness.”